Effect of phytosomal curcumin supplementation on patients with migraine

The effect of phytosomal curcumin supplementation on severity, frequency, duration of headache and inflammatory factors and oxidative stress in patients with migraine

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201129049534N2

Enrollment

Registered

2021-06-23

Start date

2022-04-04

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine headache. Migraine headache

Interventions

Intervention 1: The intervention group will receive a capsule containing Phytosomal curcumin in the amount of 250 mg of curcumin once a day after breakfast for 8 weeks. Intervention 2: The control gro

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who agree to participate in the study and complete the informed consent form. Diagnosis of migraine headache by a neurologist using the third edition of the International Headache Disorders Questionnaire. Age: 18 to 80 years old

Exclusion criteria

Exclusion criteria: Taking anticoagulants such as warfarin, heparin, aspirin, etc. Pregnancy and lactation Follow a special diet in the last 3 months Use of herbal supplements in the last 3 months

Design outcomes

Primary

Measure	Time frame
Severity of migraine headache. Timepoint: At baseline and end of the study. Method of measurement: VAS scale.;Frequency of migraine headache. Timepoint: At baseline and end of the study. Method of measurement: Number of migraine headache attacks per month.;Duration of migraine headache. Timepoint: At baseline and end of the study. Method of measurement: The average duration of migraine headache attacks per hour per headache.;Quality of life. Timepoint: At baseline and end of the study. Method of measurement: Questionnaire.;Sleep quality. Timepoint: At baseline and end of the study. Method of measurement: Sleep quality questionnaire.	—

Measure

Time frame

Severity of migraine headache. Timepoint: At baseline and end of the study. Method of measurement: VAS scale.;Frequency of migraine headache. Timepoint: At baseline and end of the study. Method of measurement: Number of migraine headache attacks per month.;Duration of migraine headache. Timepoint: At baseline and end of the study. Method of measurement: The average duration of migraine headache attacks per hour per headache.;Quality of life. Timepoint: At baseline and end of the study. Method of measurement: Questionnaire.;Sleep quality. Timepoint: At baseline and end of the study. Method of measurement: Sleep quality questionnaire.

—

Secondary

Measure	Time frame
Malondialdehyde (MDA). Timepoint: At baseline and end of the study. Method of measurement: Calorimetry.;Superoxide dismutase (SOD). Timepoint: At baseline and end of the study. Method of measurement: Calorimetry.;Total oxidant status (TOS). Timepoint: At baseline and end of the study. Method of measurement: Calorimetry.;Total Antioxidant Capacity (TAC). Timepoint: At baseline and end of the study. Method of measurement: Calorimetry.;C reactive protein (CRP). Timepoint: At baseline and end of the study. Method of measurement: Elisa.;Nitric Oxide (NO). Timepoint: At baseline and end of the study. Method of measurement: Elisa.	—

Measure

Time frame

Malondialdehyde (MDA). Timepoint: At baseline and end of the study. Method of measurement: Calorimetry.;Superoxide dismutase (SOD). Timepoint: At baseline and end of the study. Method of measurement: Calorimetry.;Total oxidant status (TOS). Timepoint: At baseline and end of the study. Method of measurement: Calorimetry.;Total Antioxidant Capacity (TAC). Timepoint: At baseline and end of the study. Method of measurement: Calorimetry.;C reactive protein (CRP). Timepoint: At baseline and end of the study. Method of measurement: Elisa.;Nitric Oxide (NO). Timepoint: At baseline and end of the study. Method of measurement: Elisa.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Bagherniya

Esfahan University of Medical Sciences

bagherniya@nutr.mui.ac.ir+98 31 3972 3138

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026